Vaccination; Infection Clinical Trial
Official title:
The Influence of Trained Immunity in COVID-19 Vaccinated Individuals
The concept of trained immunity defines the long-term functional reprogramming of innate immune cells, which is evoked by exogenous or endogenous insults and leads to an altered response towards a second challenge after return to a non-activated state and is characterized by several markers, such as specific cytokines, activation markers of innate immune cells and epigenetic modifications, e.g. H3K4me3. Vaccinations have been shown to induce trained immunity and to have heterologous effects on other infections or vaccinations. A recent article showed, that individuals who had received recombinant adjuvanted zoster vaccine (RZV) before the pandemic had a 16% lower risk of COVID-19 diagnosis and a 32% lower risk of hospitalization suggesting a protective heterologous effect of RVZ on COVID19 infections. So far, the mechanisms behind these add-on benefits of RZV vaccination are on the hypothetical level and need further experimental evidence. Therefore, we aim to investigate the specific humoral and cellular immune response towards COVID-19 vaccine in healthy individuals who were exposed to RZV 1 to 12 months before COVID-19 vaccination compared to individuals who did not receive RZV before. Particular emphasis is layed on COVID-19 vaccine non-responders and individuals with breakthrough infections indicating lower vaccine efficacy compared to those who had no breakthrough infection. The primary objective is the cytokine profile of spike protein-stimulated T, NK and NKT cells. Spike protein stimulated T, NK and NKT cells are characterized by cell surface markers, transcription factor expression, chemokine receptor expression, activation and proliferation markers and by their lineage-specific cytokine pattern. CD14+ monocytes are magnetically isolated and further characterized by cell-culture experiments imitating a training and resting period after stimulation. Epigenetic modifications by methylation of CpG regions are assessed at promoter, enhancer and regulatory gene regions of immune cell characteristic transcription factors by bisulfite conversion and pyrosequencing. Chromatin immunoprecipitation and ChIP-seq will be performed for analysis H3K4me3 associated with trained immunity. Humoral and cellular reactivity to spike protein is analyzed by adapted ELISA and neutralisation assays and by ELISpot and flow cytometry, respectively, and correlated. From our findings we expect to learn about the role of previous RZV on immunogenicity and efficacy of COVID-19 vaccination and whether mechanisms of trained immunity play a role for better responses towards COVID-19 vaccination.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05977127 -
Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly
|
Phase 2 | |
Recruiting |
NCT06048406 -
Effect of Health Education on Promoting Influenza Vaccination Health Literacy
|
N/A | |
Completed |
NCT03144518 -
Mood and Influenza Vaccine Response: A Feasibility Trial
|
N/A | |
Completed |
NCT05869201 -
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine
|
Phase 2/Phase 3 | |
Recruiting |
NCT06088563 -
Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX
|
N/A | |
Completed |
NCT05160766 -
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
|
Phase 2 | |
Recruiting |
NCT05222139 -
Monitoring COVID-19 Vaccination Response in Fragile Populations
|
||
Enrolling by invitation |
NCT05028881 -
COVID-19 Serology in People Living With HIV in Hong Kong
|
||
Recruiting |
NCT05315362 -
Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine
|
Phase 2 | |
Not yet recruiting |
NCT04848441 -
Risk of COVID-19 Infection After Vaccination
|
||
Recruiting |
NCT04920357 -
Immune Response to Vaccination Against Covid-19, a Follow up Study
|
||
Not yet recruiting |
NCT03880669 -
The 6-in-1 Vaccine Study
|
Phase 4 | |
Recruiting |
NCT05898464 -
Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV
|
Phase 4 | |
Not yet recruiting |
NCT05856396 -
Maternal Determinants of Infant Immunity to Pertussis
|
Phase 4 | |
Recruiting |
NCT05658614 -
Anti-Schistosomiasis Sm14-vaccine in Senegal
|
Phase 2 | |
Completed |
NCT05457894 -
Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women
|
Phase 3 | |
Completed |
NCT05470582 -
Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old
|
Phase 3 | |
Recruiting |
NCT05160428 -
Post Covid-19 Vaccination Development or Flare of ARD
|
||
Recruiting |
NCT04970836 -
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
|
N/A |